Insider Selling: TransMedics Group, Inc. (NASDAQ:TMDX) Director Sells 15,040 Shares of Stock

TransMedics Group, Inc. (NASDAQ:TMDX - Get Free Report) Director James R. Tobin sold 15,040 shares of the company's stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $106.43, for a total transaction of $1,600,707.20. Following the transaction, the director now owns 205,171 shares of the company's stock, valued at approximately $21,836,349.53. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

TransMedics Group Price Performance

NASDAQ:TMDX traded up $3.55 during trading hours on Friday, reaching $127.99. The company had a trading volume of 1,543,089 shares, compared to its average volume of 765,449. The firm has a market capitalization of $4.19 billion, a PE ratio of -376.44 and a beta of 1.87. The stock has a 50-day moving average of $85.54 and a two-hundred day moving average of $76.85. TransMedics Group, Inc. has a one year low of $36.42 and a one year high of $129.66. The company has a quick ratio of 8.49, a current ratio of 9.30 and a debt-to-equity ratio of 3.69.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last posted its quarterly earnings data on Tuesday, April 30th. The company reported $0.35 earnings per share for the quarter, topping the consensus estimate of ($0.05) by $0.40. The firm had revenue of $96.90 million during the quarter, compared to analysts' expectations of $83.78 million. TransMedics Group had a negative net margin of 3.43% and a positive return on equity of 8.29%. TransMedics Group's revenue was up 132.9% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.08) EPS. Analysts forecast that TransMedics Group, Inc. will post -0.14 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts have commented on the stock. JPMorgan Chase & Co. upped their target price on shares of TransMedics Group from $105.00 to $127.00 and gave the stock an "overweight" rating in a research report on Wednesday. Canaccord Genuity Group boosted their price target on TransMedics Group from $102.00 to $117.00 and gave the stock a "buy" rating in a research report on Wednesday. TD Cowen upped their target price on TransMedics Group from $100.00 to $130.00 and gave the stock a "buy" rating in a research report on Wednesday. Morgan Stanley raised their price objective on shares of TransMedics Group from $75.00 to $95.00 and gave the company an "equal weight" rating in a research report on Wednesday, February 28th. Finally, Piper Sandler reiterated an "overweight" rating and issued a $120.00 target price (up from $95.00) on shares of TransMedics Group in a report on Wednesday. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $119.00.

Hedge Funds Weigh In On TransMedics Group

A number of hedge funds and other institutional investors have recently made changes to their positions in TMDX. Venturi Wealth Management LLC bought a new position in shares of TransMedics Group during the 1st quarter valued at about $30,000. Fidelis Capital Partners LLC bought a new stake in TransMedics Group in the 1st quarter valued at approximately $35,000. Cutler Group LLC CA boosted its position in TransMedics Group by 600.0% during the 3rd quarter. Cutler Group LLC CA now owns 700 shares of the company's stock worth $38,000 after acquiring an additional 600 shares during the last quarter. RiverPark Advisors LLC bought a new position in shares of TransMedics Group during the 3rd quarter worth approximately $60,000. Finally, First Horizon Advisors Inc. raised its holdings in shares of TransMedics Group by 26.8% in the fourth quarter. First Horizon Advisors Inc. now owns 1,049 shares of the company's stock valued at $83,000 after purchasing an additional 222 shares during the last quarter. 99.67% of the stock is owned by institutional investors.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.